Clinical Trial

Feasibility of FMISO in Brain Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well ¹⁸F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors. FMISO provides information about the oxygen levels in a tumor, which may affect how the tumor behaves. PET/MRI imaging produces images of the brain and how the body functions. FMISO PET/MRI may help investigators see how much oxygen is getting in the brain tumors.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2018-08-25; most recent amendment 2025-03-20.
Status change: Not Yet Recruiting → Recruiting 2019-08-14
Trial Details
NCT Number NCT03649880
Lead Sponsor OHSU Knight Cancer Institute
Collaborators: National Cancer Institute (NCI), Oregon Health and Science University, Weill Cornell University
Conditions Malignant Brain Neoplasm
Enrollment 50 participants
Start Date 2019-06-01
Primary Completion 2029-01-31 (estimated)
Study Completion 2030-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-25